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Abstract 
Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evalu-
ation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and 
morbidity.
Methods: Baseline data, stratified for prior cardiovascular disease (CVD), were compared using multivariable logistic 
regression analysis to establish whether region is an independent determinant of achieved targets for glycated hemo-
globin (HbA1c), blood pressure (BP), and low-density lipoprotein (LDL)-cholesterol.
Results: Independent of CVD history, US participants were more often of non-White origin and had a longer history 
of type 2 diabetes, higher body weight, and higher baseline HbA1c. They had substantially lower systolic and diastolic 
BP, and a marginally lower LDL-cholesterol level. Fewer US participants were diagnosed with left ventricular dysfunc-
tion. In the largest group of patients, those with prior CVD and the highest cardiovascular risk, US participants were 
more often female, had a higher waist circumference, and had a decreased estimated glomerular filtration rate, but 
less frequently prior myocardial infarction or angina pectoris.
Conclusions: There were baseline differences between US and European participants. These differences may result 
from variation in regional targets for cardiovascular risk factor management, and should be considered in the analysis 
and reporting of the trial results.
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Background
The Liraglutide Effect and Action in Diabetes: Evaluation 
of cardiovascular outcome Results (LEADER) trial [1] is 
one of at least 16 cardiovascular outcome trials in type 2 
diabetes (T2D) that will report before 2020 [2]. Driven by 
regulatory requirements to demonstrate cardiovascular 
safety, trial sample sizes are large. To recruit 10‒20,000 
participants per trial, there are 17–27 countries per trial, 
resulting in a wider range of racial and ethnic participa-
tion, as well as greater variation in clinical practice pat-
terns than in previous T2D studies [2]. The clinical 
usefulness of trial data obtained for a particular clinician 
or policy-maker depends on how well the trial popula-
tion mirrors the patients in that clinician’s practice, or 
the population for whom the policy is developed. This 
external validity is determined by inclusion criteria, 
but also by patients’ enrolment, retention, and proto-
col adherence. The age distribution of trial participants 
in seven large diabetes trials often did not reflect that 
of a contemporary British T2D patient population [3]. 
Most ongoing diabetes cardiovascular outcome trials are 
being conducted in populations with high cardiovascular 
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risk with a long history of T2D [2]. Women and ethnic 
minorities are under-represented in US-based clini-
cal trials, although these groups have disproportionally 
higher rates of chronic diseases [4]. The generalizability 
of results even from well-performed trials may be jeop-
ardized when participants differ from the clinical popula-
tion with respect to attributes that modify treatment [5]. 
In a multivariate model, female sex, renal insufficiency, 
and heart failure were significant predictors of not par-
ticipating in a trial [6]. Such clinical factors are important 
because they may modify treatment effects. The table of 
baseline characteristics in trial reports should focus on 
baseline factors associated with primary outcomes [7].
Patient enrolment is likely to be dependent on the 
specific types of investigator practices (generalist, dia-
betologist, cardiologist, nephrologist, etc.) and on the 
healthcare systems they operate within. A UK study sug-
gests that selection of study sites should aim to represent 
the general medical management of T2D patients [8]. It 
might be questioned whether such a strategy is economi-
cally and logistically possible in large global trials.
We seek to examine whether there are important base-
line differences in cardiovascular risk markers among 
LEADER participants enrolled in the US and Europe. 
This study of these two populations was prompted by the 
substantial differences between the US and Europe, for 
example with respect to demographics; cultural norms 
regarding diet, activity, and other health behaviors; pre-
vailing treatment guidelines for glycemia, blood pressure 
(BP), lipids, and cardiovascular management; and fund-
ing and nature of healthcare systems [9, 10]. We exam-
ined baseline demographic and clinical characteristics 
of LEADER participants in the US and Europe without a 
priori hypotheses. Such an exploratory investigation may 
generate hypotheses about possible heterogeneity [11], 
and be informative for potential post hoc analyses [11, 
12].
Methods
Study design and participants
We used baseline data from LEADER (NCT01179048), 
a phase 3b, multicenter, international, randomized, 
double-blind, placebo-controlled clinical trial with long-
term follow-up in 9340 patients with T2D. This trial 
will provide data on the cardiovascular safety of lira-
glutide compared to placebo. The trial design has been 
described in more detail previously [1]. Enrolment took 
place from September 2010 until April 2012. Patients 
with T2D who were either drug-naive or treated with oral 
blood glucose-lowering agents or selected insulin regi-
mens (human neutral protamine Hagedorn, long-acting 
analog, or premixed) were eligible. LEADER enrolled two 
distinct populations of high-risk patients: (1) patients 
with prior cardiovascular disease (CVD), ≥50  years old 
(defined as having one or more of the following car-
diovascular comorbidities: prior myocardial infarction, 
stoke, transient ischemic attack, arterial revasculariza-
tion, chronic heart failure [New York Heart Associa-
tion {NYHA} class II–III], or chronic renal failure); (2) 
patients without prior CVD, ≥60  years old with one or 
more cardiovascular risk factors: micro-albuminuria or 
proteinuria, hypertension and left ventricular hypertro-
phy by electrocardiogram (ECG) or imaging, or ankle-
brachial index <0.9. Enrolment of approximately 400 
patients with moderate (estimated glomerular filtration 
rate [eGFR] 30‒59 mL/min/1.73 m2) and 200 with severe 
(eGFR <30 mL/min/1.73 m2) renal impairment was also 
pre-specified [1].
The present analysis compares baseline data between 
US and European populations from LEADER, stratified 
by patients’ cardiovascular history. The European popula-
tion includes all patients enrolled from Austria, Belgium, 
Czech Republic, Denmark, Finland, France, Germany, 
Greece, Ireland, Italy, the Netherlands, Norway, Poland, 
Romania, Serbia, Spain, Sweden, Turkey, and the UK. The 
trial was designed and conducted according to the dec-
laration of Helsinki and approved by local ethical com-
mittees. All subjects signed informed consent before any 
study procedure was performed.
Outcome measures
Baseline participant characteristics were recorded at 
screening visits (Table  1). Concomitant illness was any 
illness present at the start of the trial, including history 
of CVD (myocardial infarction, stroke, angina pectoris, 
arrhythmia, left ventricular dysfunction). Concomitant 
medication use was defined as use of any medication 
other than trial product at randomization. Data on blood 
glucose-lowering medication, the number and type of 
antihypertensive medication, statin use, other lipid-low-
ering medication, and aspirin were collected. Height, 
body weight, and waist circumference were measured 
without shoes and in light clothing. Systolic BP (SBP) and 
diastolic BP (DBP) were measured after at least 5  min 
rest in the sitting position, with the legs uncrossed and 
the back and arm supported. Blood samples were col-
lected at randomization and assessed in a central labora-
tory for glycated hemoglobin (HbA1c), lipids, creatinine, 
and albumin:creatinine ratio (ACR).
 Target levels
In 2010, ‘general’ HbA1c goals varied among Euro-
pean countries between <6.5  % and <7.0  % (<48 and 
<53 mmol/mol) [9]. The American Diabetes Association 
(ADA) recommended in 2010 that less stringent HbA1c 
goals than the general goal of 7.0 % (53 mmol/mol) may 
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Table 1 Baseline differences between Europe and US patients, stratified by history of prior CVD
No prior CVD group (n = 1013) Prior CVD group (n = 4996)
Europe (n = 599) USA (n = 414) P value Europe (n = 2922) USA (n = 2074) P value
Gender, female (n,  %) 223 (37.2) 177 (42.8) 0.077 857 (29.3) 710 (34.2) 0.001
Age, years (mean, SD) (n,  %) 66.0 (5.0) 66.1 (5.6) 0.783 64.6 (7.5) 64.3 (7.7) 0.166
 50–59 10 (1.7) 8 (1.9) 798 (27.3) 589 (28.4)
 60–69 454 (75.8) 310 (74.9) 1364 (46.7) 971 (46.8)
 70–79 127 (21.2) 84 (20.3) 0.355 694 (23.8) 451 (21.7) 0.240
 80–89 8 (1.3) 12 (2.9) 65 (2.2) 62 (3.0)
 90–99 0 (0) 0 (0) 1 (0.0) 1 (0.0)
Diabetes duration, years (mean, SD) 11.2 (6.8) 13.2 (7.9) <0.001 11.7 (7.6) 13.5 (8.8) <0.001
Race (n,  %)
 Asian 3 (0.5) 9 (2.2) 25 (0.9) 37 (1.8)
 Black 2 (0.3) 101 (24.4) <0.001 14 (0.5) 366 (17.6) <0.001
 White 592 (98.8) 295 (71.3) 2871 (98.3) 1622 (78.2)
 Other 2 (0.3) 9 (2.2) 12 (0.4) 49 (2.4)
Body weight, kg (mean, SD) 94.0 (18.1) 98.9 (23.4) <0.001 93.6 (18.6) 101.1 (21.8) <0.001
BMI, kg/m2 (mean, SD) (n,  %) 33.0 (5.6) 34.4 (6.9) <0.001 32.7 (5.8) 34.6 (6.8) <0.001
 18–25 25 (4.2) 24 (5.8) 181 (6.2) 96 (4.6)
 25–30 176 (29.4) 91 (22.0) 843 (28.9) 438 (21.1)
 30–35 216 (36.1) 125 (30.2) <0.001 1024 (35.0) 686 (33.1) <0.001
 35–40 113 (18.9) 91 (22.0) 554 (19.0) 478 (23.0)
 >40 69 (11.5) 83 (20.0) 316 (10.8) 375 (18.1)
Waist circumference, cm (mean, SD) 112.2 (15.5) 114.1 (18.4) 0.072 111.2 (15.3) 114.5 (17.0) <0.001
HbA1c,  % (mean, SD) 8.4 (1.3) 8.9 (1.6) <0.001 8.3 (1.3) 8.8 (1.5) <0.001
HbA1c at target (n,  %)
 ≤7.5 % 186 (31.1) 68 (16.4) <0.001 880 (30.1) 481 (23.2) <0.001
 ≤7 % 49 (8.2) 18 (4.3) 0.016 264 (9.0) 157 (7.6) 0.066
SBP, mmHg (mean, SD) 144.1 (17.5) 135.5 (17.1) <0.001 140.0 (18.4) 133.3 (18.5) <0.001
DBP, mmHg (mean, SD) 81.0 (9.7) 76.0 (9.5) <0.001 78.5 (10.2) 74.7 (10.5) <0.001
BP at target (n,  %) (Europe < 140/80 and USA 130/80 
mmHg)
146 (24.4) 134 (32.4) 0.005 974 (33.3) 800 (38.6) <0.001
LDL, mmol/L (mean, SD) 2.5 (0.9) 2.3 (0.9) <0.001 2.3 (0.9) 2.2 (0.9) 0.113
At target (n,  %) 319 (53.3) 273 (65.9) <0.001 1934 (66.2) 757 (36.5) <0.001
HDL, mmol/L (mean, SD) 1.3 (0.3) 1.2 (0.4) 0.104 1.2 (0.3) 1.2 (0.3) 0.008
Triglyceride, mmol/L (mean, SD) 2.0 (1.3) 2.0 (2.0) 0.749 2.1 (1.8) 2.0 (1.5) 0.038
Creatinine, μmol/L (mean, SD) 71.6 (14.6) 73.1 (15.6) 0.106 85.4 (31.2) 94.7 (38.2) <0.001
ACR, mg/mmol (mean, SD) 10.6 (30.5) 14.8 (50.5) 0.135 16.4 (57.3) 26.5 (82.0) <0.001
eGFR (mean, SD) 90.0 (24.0) 90.3 (20.5) 0.847 81.3 (26.8) 74.8 (27.1) <0.001
Renal function, eGFR (mL/min/1.73 m2) (n,  %)
 Normal (≥ 90) 268 (44.7) 181 (43.7) 1079 (36.9) 591 (28.5)
 Mild decline (60–90) 331 (55.3) 233 (56.3) 0.748 1191 (40.8) 809 (39.0) <0.001
 Moderate decline (30–60) 0 (0.0) 0 (0.0) 605 (20.7) 625 (30.1)
 Severe decline (< 30) 0 (0.0) 0 (0.0) 47 (1.6) 49 (2.4)
Micro-albuminuria (n,  %) 246 (41.1) 233 (56.3) <0.001 347 (11.9) 248 (12.0) 0.930
Macro-albuminuria (n,  %) 31 (5.2) 65 (15.7) <0.001 77 (2.6) 66 (3.2) 0.253
Myocardial infarction (n,  %) 0 (0) 0 (0) 567 (19.4) 321 (15.5) <0.001
Stroke (n,  %) 0 (0) 0 (0) 434 (14.9) 289 (13.9) 0.363
Angina pectoris (n,  %) 0 (0) 5 (0.8) 0.062 1114 (38.1) 617 (29.7) <0.001
Arrhythmia (n,  %) 57 (9.5) 45 (10.9) 0.482 479 (16.4) 394 (19.0) 0.017
Left ventricle dysfunction (n,  %) 188 (31.4) 56 (13.5) <0.001 702 (24.0) 379 (18.3) <0.001
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be appropriate for patients with advanced macrovascu-
lar complications [10]. An ADA/European Association 
for the Study of Diabetes position statement stated that 
HbA1c goals between 7.5 and 8.0  % (58 and 64  mmol/
mol), or even slightly higher, are appropriate for patients 
with established vascular complications or extensive 
comorbid conditions [13]. Previously, SBP and DBP tar-
gets also differed among European countries, between 
<130 and 140  mmHg and <80 or <85  mmHg, respec-
tively [9]. Until 2013, the ADA recommended a BP tar-
get of <130/80  mmHg; in 2014, US guidance on BP in 
diabetes was relaxed to <140/<80 mmHg [14]. Similarly, 
at the onset of the study in 2010, low-density lipopro-
tein (LDL)-cholesterol targets differed between Euro-
pean countries, ranging from <100 mg/dL (2.6 mmol/L) 
and 115  mg/dL (3  mmol/L) for primary prevention [9]. 
At that time, the LDL target for US participants was 
<100 mg/dL (<2.6 mmol/L) (no prior CVD) or <70 mg/
dL (<1.8 mmol/L) (prior CVD) [10], with the latter goal 
termed ‘an option’ in the 2014 recommendations [14].
For the present study, we defined two different HbA1c 
targets: ≤7.0 % and ≤7.5 % (≤53 and ≤58 mmol/mol); for 
both CVD strata and both regions [15]. BP at target was 
defined as <140/<80 and <130/<80 mmHg for European 
and US participants, respectively. LDL-cholesterol at tar-
get was defined as <100 mg/dL (<2.6 mmol/L) for Euro-
pean participants and <100  mg/dL (<2.6  mmol/L) (no 
prior CVD group) or <70  mg/dL (<1.8  mmol/L) (prior 
CVD group) for US participants.
Statistical analyses
All analyses were performed using SAS software (version 
9.3). Continuous variables were reported as means with 
standard deviations, categorical variables as numbers 
and percentages. Because a patient’s history of CVD is 
likely to be related to the cardiovascular outcome of the 
LEADER trial, the analysis of differences between regions 
(US vs. Europe) was stratified by prior and no prior CVD. 
We used t-tests for continuous variables or Chi square 
test for class variables. Logistic regression analyses were 
ACR albumin:creatinine ratio, BMI body mass index, BP blood pressure, CVD cardiovascular disease, DBP diastolic blood pressure, eGFR estimated glomerular filtration 
rate, HDL high-density lipoprotein, LDL low-density lipoprotein, OAD oral antidiabetic drug, SBP systolic blood pressure, SD standard deviation
P values are for difference between region (Europe vs. USA) on covariates (t test) and factors (Chi square)
Table 1 continued
No prior CVD group (n = 1013) Prior CVD group (n = 4996)
Europe (n = 599) USA (n = 414) P value Europe (n = 2922) USA (n = 2074) P value
Smoking (n,  %)
 Current 83 (13.9) 57 (13.8) 407 (13.9) 278 (13.4)
 Never 248 (41.4) 187 (45.2) 0.455 946 (32.4) 754 (36.4) 0.013
 Previous 268 (44.7) 170 (41.1) 1569 (53.7) 1042 (50.2)
Pre-trial treatment (n,  %)
 None/diet 16 (2.7) 41 (9.9) 102 (3.5) 226 (10.9)
 Insulin only 19 (3.2) 22 (5.3) <0.001 200 (6.8) 210 (10.1) <0.001
 OADs only 380 (63.4) 213 (51.4) 1624 (55.6) 973 (46.9)
 Insulin + OADs 184 (30.7) 138 (33.3) 996 (34.1) 665 (32.1)
Number of oral blood glucose-lowering drugs (n,  %)
 No OAD 219 (36.6) 201 (48.6) 1298 (44.4) 1101 (53.1)
 1 OAD 155 (25.9) 83 (20.0) 0.424 707 (24.2) 428 (20.6) 0.013
 2 OADs 199 (33.2) 109 (26.3) 826 (28.3) 463 (22.3)
 >2 OADs 26 (4.3) 21 (5.1) 91 (3.1) 82 (4.0)
BP-lowering medication (n,  %) 517 (86.3) 360 (87.0) 0.767 2729 (93.4) 1930 (93.1) 0.639
Number of antihypertensive medications (n,  %)
 0 82 (13.7) 54 (13.0) 193 (6.6) 144 (6.9)
 1 225 (37.6) 182 (44.0) 0.018 731 (25.0) 607 (29.3) 0.001
 2 172 (28.7) 126 (30.4) 1315 (45.0) 920 (44.4)
 3 93 (15.5) 44 (10.6) 533 (18.2) 324 (15.6)
 4 27 (4.5) 8 (1.9) 150 (5.1) 79 (3.8)
Statin (n,  %) 362 (60.4) 298 (72.0) <0.001 2369 (81.1) 1704 (82.2) 0.330
Other lipid-lowering drugs (n,  %) 2 (0.3) 11 (2.7) 0.001 39 (1.3) 44 (2.1) 0.032
Aspirin (n,  %) 192 (32.1) 198 (47.8) <0.001 1934 (66.2) 1441 (69.5) 0.014
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then used to determine whether region (Europe/US) 
was an independent determinant of achieving target for 
HbA1c, BP, and LDL-cholesterol, respectively. These 
analyses were adjusted for several well-known possible 
confounding variables: age, sex, diabetes duration, race, 
pre-trial diabetes treatment, body mass index (BMI) cat-
egory, and renal function (creatinine, ACR, and eGFR); 
these variables were included based on subject matter 
considerations and availability of data. See Tables 2, 3, 4 
for details. P values ≤0.01 were considered statistically 
significant.
Results
Baseline differences between Europe and US patients: 
whole cohort
Irrespective of CVD history, US and European partici-
pants differed on several important CVD risk factors 
and other diabetes complications (Table 1). US partici-
pants were more often of non-White origin, had longer 
T2D duration, had higher body weight, and were more 
often in the highest BMI categories compared with 
European participants. Furthermore, US participants 
had a 0.5  % higher HbA1c and a different distribution 
of blood glucose-lowering treatments than European 
participants. Significantly fewer US participants were 
at HbA1c target ≤7.5  % (≤58  mmol/mol). However, 
US participants had substantially lower SBP and DBP, 
and marginally lower LDL-cholesterol level than Euro-
pean participants. Significantly more European than 
US participants were diagnosed with left ventricular 
dysfunction.
Baseline differences between Europe and US patients: 
group without prior CVD
In the group without prior CVD, US participants were 
more frequently at BP target (with different target levels 
in both regions) and more frequently at LDL target (with 
comparable targets in both regions, but with significantly 
more US participants on lipid-modifying medications) 
than participants from Europe. In addition, more US than 
European participants without prior CVD had micro- or 
macro-albuminuria, but the percentages of these patients 
with decreased kidney function did not differ between 
regions (Table 1).
Table 2 Determinants of being at HbA1c target at baseline (HbA1c ≤ 7.5 %), stratified by prior CVD status
Logistic multivariable regression modelling the probability of being at HbA1c target, adjusted for: age, sex, diabetes duration, race, pre-trial diabetes treatment, BMI 
category and renal function (creatinine, ACR, eGFR)
ACR albumin:creatinine ratio, BMI body mass index, CI confidence interval, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, OAD oral antidiabetic 
drug
Overall P values relating to the significance of that factor
No prior CVD group (n = 1013) Prior CVD group (n = 4996)
Odds ratio 95 % CI P value Odds ratio 95 % CI P value
Region (Europe as reference group) 0.475 0.316; 0.704 <0.001 0.762 0.647; 0.896 0.001
Age (per year) 1.015 0.981; 1.050 0.393 1.032 1.020; 1.043 <0.001
Sex (male as reference group) 0.485 0.169; 1.271 0.148 0.834 0.685; 1.011 0.065
Diabetes duration (per year) 0.976 0.951; 1.000 0.055 0.976 0.967; 0.986 <0.001
Race (white as reference group)
 Asian 0.970 0.139; 4.258 0.598 0.257; 1.223
 Black 1.691 0.672; 4.244 0.718 1.069 0.780; 1.452 0.266
 Other 1.358 0.195; 6.005 0.604 0.258; 1.248
Pre-trial diabetes treatment (none, diet as reference group)
 Insulin + OADs 1.080 0.475; 2.710 0.800 0.586; 1.102
 Insulin only 0.956 0.272; 3.215 0.543 0.532 0.349; 0.805 <0.001
 OADs only 1.365 0.629; 3.312 1.248 0.930; 1.693
BMI (18–25 as reference group) (kg/m2)
 25–30 0.628 0.286; 1.446 1.220 0.871; 1.730
 30–35 0.788 0.369; 1.780 0.235 1.010 0.723; 1.427 0.049
 35–40 0.619 0.273; 1.464 1.036 0.729; 1.488
 >40 1.082 0.476; 2.575 0.824 0.561; 1.219
Creatinine, per μmol/L 0.966 0.915; 1.015 0.179 0.998 0.993; 1.002 0.288
ACR, per mg/mmol 1.002 0.997; 1.005 0.421 1.000 0.999; 1.002 0.471
eGFR, per mL/min/1.73 m2 0.967 0.931; 1.000 0.048 0.992 0.986; 0.998 0.007
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Baseline differences between Europe and US patients: 
group with prior CVD
In the largest group of patients, those with prior CVD 
and the highest cardiovascular risk, US participants were 
more often female and had a higher waist circumference 
than participants from Europe. A higher percentage of 
US participants were at BP target and a lower percentage 
of US participants with prior CVD attained LDL target 
than participants from Europe. The numbers of antihy-
pertensive medications per patient were broadly similar, 
with slightly more US participants receiving none or one 
and slightly fewer receiving two, three, or four of these 
medications, compared with European participants. 
More US than European participants with prior CVD 
had decreased eGFR. The percentages of participants 
with a prior myocardial infarction or angina pectoris also 
differed significantly between regions (Table 1).
Participants with HbA1c at target
Among participants without prior CVD, after multivari-
able adjustment, the odds ratio (OR) for US participants 
to have HbA1c ≤7.5 % (≤58 mmol/mol) at baseline was 
0.475 (95  % confidence interval [CI] 0.316; 0.704) com-
pared to European participants (P < 0.001). In the group 
of participants with prior CVD, the corresponding OR 
for US participants was 0.762 (95  % CI 0.647; 0.896) 
(Table 2). With a target ≤7 % (≤53 mmol/mol), the OR 
for US participants to be at target at baseline was 0.532 
(95  % CI 0.260; 1.020) (not significant [NS]) in the no 
prior CVD group, and 0.839 (95 % CI 0.646; 1.084) (NS) 
in the prior CVD group.
Participants with BP at target
After adjustment for age, sex, race, diabetes duration, 
BMI class, number of hypertension medications, renal 
Table 3 Determinants of being at BP target (Europe <140/80 mmHg, USA <130/80 mmHg) at baseline stratified by prior 
CVD status
Logistic multivariable regression modelling the probability of being at BP target, adjusted for: age, sex, diabetes duration, race, BMI category, number of 
antihypertensive medications, renal function (creatinine, ACR, eGFR), and micro- and macro-albuminuria
ACR albumin:creatinine ratio; BMI body mass index; BP blood pressure; CI confidence interval; CVD cardiovascular disease; eGFR estimated glomerular filtration rate
Overall P values relating to the significance of that factor
No prior CVD group (n = 1013) Prior CVD group (n = 4996)
Odds ratio 95 % CI P value Odds ratio 95 % CI P value
Region (Europe as reference group) 1.662 1.150; 2.402 0.007 1.314 1.136; 1.520 <0.001
Age (per year) 0.959 0.928; 0.990 0.009 0.992 0.982; 1.002 0.115
Sex (male as reference group) 0.823 0.341; 1.707 0.641 1.070 0.901; 1.270 0.438
Diabetes duration (per year) 1.020 0.998; 1.042 0.082 1.003 0.995; 1.012 0.472
Race (white as reference group)
 Asian 1.758 0.457; 6.795 0.880 0.483; 1.560 0.064
 Black 1.070 0.517; 2.318 0.604 0.724 0.551; 0.946
 Other 0.442 0.063; 1.987 0.621 0.304; 1.189
BMI (18–25, reference group) ( kg/m2)
 25–30 1.217 0.577;2.677 0.889 0.655; 1.212
 30–35 0.913 0.436;1.998 0.009 0.793 0.587; 1.077 0.008
 35–40 0.511 0.229;1.177 0.693 0.503; 0.957
 >40 0.650 0.283;1.533 0.623 0.442; 0.879
Number of antihypertensive medications
 0 (reference group)
 1 1.142 0.698; 1.897 0.918 0.693; 1.221
 2 0.716 0.415; 1.244 0.096 1.010 0.772; 1.326 <0.001
 3 0.650 0.333; 1.256 0.648 0.477; 0.881
 4 1.024 0.360; 2.670 0.646 0.424;0.975
Creatinine, per umol/L 0.986 0.942; 1.021 0.488 1.004 1.000; 1.008 0.058
ACR, per mg/mmol 0.992 0.983; 0.999 0.013 0.994 0.992; 0.996 <0.001
eGFR,per mL/min/1.73 m2 0.985 0.956; 1.007 0.239 0.998 0.992; 1.003 0.334
Micro-albuminuria 0.895 0.628; 1.275 0.538 0.947 0.774; 1.155 0.592
Macro-albuminuria 0.918 0.507; 1.635 0.775 1.562 1.060; 2.287 0.024
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function, and well as micro- and macro-albuminuria, 
US participants were more often at target BP than par-
ticipants from Europe, irrespective of their CVD history 
(no prior CVD OR 1.662; 95 % CI 1.150;2.402; p = 0.007; 
prior CVD 1.314; 95  % CI 1.136; 1.520; P  <  0.001) 
(Table 3).
Participants with LDL at target
US participants with no prior CVD were more often at 
LDL target at baseline, with a multivariable adjusted OR 
of 1.616 (95 % CI 1.116; 2.355; P = 0.011) compared with 
European participants. In contrast, in participants with 
prior CVD, US participants were less likely to be at LDL 
target than European participants (OR 0.248; 95  % CI 
0.212; 0.290; P < 0.001). Not surprisingly, statin use was 
an independent determinant for achieving LDL target, 
irrespective of whether it was prescribed as primary or 
secondary CVD prevention (Table 4).
Discussion
This study identified relevant differences in baseline car-
diovascular risk profiles between European and US par-
ticipants in the LEADER trial. These differences should be 
considered in the analysis and reporting of the trial results.
LEADER aims to formally assess the cardiovascular 
safety of liraglutide, as reflected in the number of cardio-
vascular events. The trial population consists of people 
with/without history of CVD. The large number of sub-
jects, as well as the number of study sites, will ensure the 
results reflect wide clinical practice, and thus the robust-
ness of the primary results. However, whether liraglutide 
is noninferior to placebo [1] in subgroups will at least 
partially depend on the baseline risk of the participants. 
The European and US populations in LEADER differed 
in many factors related to cardiovascular risk, including 
race, BMI, HbA1c, SBP and DBP, ventricular dysfunc-
tion, and, in the group without prior CVD, albuminuria. 
In some aspects, US participants may have a lower car-
diovascular risk because of their substantially lower BP 
level and lower prevalence of left ventricular dysfunction, 
but this could be counteracted by higher cardiovascular 
risk because of higher BMI and HbA1c. The baseline dif-
ferences identified should be explored in relation to the 
overall trial results, once reported. Specifically, testing 
for heterogeneity of the treatment effect and interactions 
between subgroups would be needed to evaluate whether 
these differences impact upon the generalizability of the 
overall trial findings. Thus, these baseline findings should 
Table 4 Determinants for  being at  LDL target at  baseline (Europe <100  mg/dL, USA <100  mg/dL for  no prior CVD 
and <70 mg/dL for prior CVD group)
Logistic multivariable regression modelling the probability of being at LDL target, adjusted for: age, sex, diabetes duration, race, BMI category, statin use, aspirin use, 
and renal function (creatinine, ACR, eGFR)
ACR albumin:creatinine ratio, BMI body mass index, CI confidence interval, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, LDL low-density 
lipoprotein
Overall P values relating to the significance of that factor. Stratified by prior CVD status
No prior CVD group (n = 1013) Prior CVD group (n = 4996)
Odds ratio 95 % CI P value Odds ratio 95 % CI P value
Region (Europe as reference group) 1.616 1.116; 2.355 0.011 0.248 0.212; 0.290 <0.001
Age (per year) 1.038 1.006; 1.072 0.020 1.012 1.001; 1.023 0.032
Sex (male as reference group) 0.542 0.311; 1.009 0.053 0.535 0.444; 0.644 <0.001
Diabetes duration (per year) 1.011 0.989; 1.035 0.330 1.004 0.995; 1.013 0.358
Race (white as reference group)
 Asian 0.632 0.136; 3.479 1.226 0.664; 2.275
 Black 0.710 0.371; 1.339 0.633 0.773 0.581; 1.023 0.226
 Other 1.53 0.313; 8.783 0.759 0.389; 1.451
BMI (18–25, reference group) (kg/m2)
 25–30 0.571 0.239; 1.298 1.029 0.735; 1.438
 30–35 0.836 0.353; 1.884 0.224 1.083 0.778; 1.503 0.472
 35–40 0.879 0.361;2.049 1.105 0.782; 1.560
 >40 0.935 0.375; 2.246 1.287 0.891; 1.856
Statin use (no as reference) 4.669 3.352; 6.550 <0.001 4.276 3.526; 5.202 <0.001
Aspirin use (no as reference) 1.055 0.750; 1.482 0.759 1.369 1.174; 1.597 <0.001
Creatinine, per umol/L 1.007 0.982; 1.038 0.607 0.995 0.991; 1.000 0.034
ACR, per mg/mmol 0.999 0.995; 1.003 0.485 0.999 0.997; 1.000 0.017
eGFR per mL/min/1.73 m2 1.006 0.993; 1.025 0.360 0.994 0.988; 1.000 0.036
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be interpreted with caution, but may inform additional 
analyses. Calculating an individual’s 10-year CVD risk in 
people without prior CVD may also help identify which 
patients benefit most from the treatments under study 
[15, 16].
Regional differences are not unique to LEADER: they 
probably exist in all global trials, and in cardiovascu-
lar outcome trials in diabetes in particular. The analysis 
in this study provides more detail on potential relevant 
differences, and hence will support interpretation of the 
final results. The implications of these data, which show 
differences related to baseline cardiovascular risk man-
agement between US and European participants, may 
also be relevant in shaping future trial designs with simi-
lar populations. Such trial designs will need to account 
for factors pertaining to cardiovascular risk.
Strengths of this study include the large patient groups 
involved and investigation of the role of the ‘region’, 
independently from patient-related anthropometric and 
disease-related factors. Region, i.e. Europe or US (a cul-
tural-, socio-economic-, and healthcare-related charac-
teristic), was the most important factor associated with 
participants achieving HbA1c, BP, and LDL targets. Many 
of the baseline differences between the US and Europe 
appear driven by variation in regional targets for cardio-
vascular risk management. However, the role of ‘region’ 
may not only be determined by guidelines and physi-
cian prescription patterns, but also the sites that enrolled 
patients, the way they did so, and patient‒physician rela-
tionships. A recent systematic review and meta-analysis 
of randomized controlled trials demonstrated that inten-
sive glycemic control in patients with T2D was associated 
with increases in all-cause mortality, cardiovascular mor-
tality, and severe hypoglycemia in study populations from 
North America compared with the rest of the world [17]. 
Its authors emphasized the need for further investigation 
into these findings [17]. The choice of participating cent-
ers can also influence the generalizability of trial results. 
For example, among >55,000 high-risk patients present-
ing with non-ST-segment elevation acute coronary syn-
drome at 443 US hospitals, 1397 (2.5  %) patients were 
enrolled in a clinical trial. The latter were more often 
cared for by cardiologists at hospitals capable of cathe-
ter-based and surgical revascularization—which might 
explain the high rates of revascularization among clinical 
trial patients [6]. Such discrepancies in care and patient 
characteristics would suggest that the data from this and 
similar cardiovascular studies cannot be extrapolated 
to the broad type 2 diabetes population. In the global 
Trial to Evaluate Cardiovascular Outcomes after Treat-
ment with Sitagliptin (TECOS), regional differences were 
noted, with lower BP and cholesterol levels in US par-
ticipants, compared to participants both from western 
and eastern Europe. Treatment target achievement was 
also associated with the type of prior vascular disease 
[18]. Therefore, region-specific data about the centers 
that enrolled patients (for example, academic sites, rural 
sites etc.), and region-specific loss-to-follow-up data 
would enable readers to judge the applicability of the trial 
results for their practice population.
LEADER was undertaken to assess the cardiovascular 
safety of liraglutide. A large set of exploratory subgroup 
analyses have been pre-specified to assess the effect of 
(among others) sex, BMI, region, cardiovascular risk, 
chronic heart failure, and severe chronic renal failure on 
the primary composite endpoint [1]. The present study 
demonstrates the relevance of these planned subgroup 
analyses and of evaluating any heterogeneity in out-
comes. In this respect, it could also be relevant to present 
detailed data about sites of enrolment and loss to follow-
up. Finally, patient-level meta-analysis of the CVD trials 
underway would allow for deeper exploration of these 
issues, as sufficient sample size of many subgroups would 
be available [19].
Conclusions
This study demonstrated important baseline differences 
between US and European participants in the LEADER 
trial. These differences may be the result of regional vari-
ations in targets for cardiovascular risk factor manage-
ment. These factors should be considered in the analysis 
and reporting of the trial results and may also be relevant 
for potential post hoc investigations.
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